Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Brukinsa“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · Zanubrutinib is a mild inducer of CYP3A and CYP2C19. Concomitant use of zanubrutinib can decrease the plasma c
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is a mild inducer of CYP3A and CYP2C19. Concomitant use of zanubrutinib can decrease the plasma c
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is primarily metabolized by cytochrome P450 enzyme 3A (CYP3A).
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is primarily metabolized by cytochrome P450 enzyme 3A (CYP3A).
Eintrag öffnenBrukinsa · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenBrukinsa · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenBrukinsa · 4.8 Undesirable effects · 1
Eintrag öffnenBrukinsa · 4.8 Undesirable effects · 2
Eintrag öffnenBrukinsa · 4.8 · 10 Fatigue§ Very common (18) 1 General disorders and Fatigue Very common (14) 1 administration site conditions
Eintrag öffnenBrukinsa · 4.8 · 11 Skin and Pruritus Common (7) 0 subcutaneous Dermatitis exfoliative generalized Unknown Unknown tissue disor
Eintrag öffnenBrukinsa · 4.8 · 34 Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanub
Eintrag öffnenBrukinsa · 4.8 · 35 Neutropenia§ Very Common (30) 21 Blood and lymphatic system Febrile neutropenia Common ( 2) 2 disorders Thr
Eintrag öffnenBrukinsa · 4.8 · 36 Table 4: Adverse reactions of zanubrutinib in combination with obinutuzumab reported in clinical study BGB-
Eintrag öffnenBrukinsa · 4.8 · 37 † Based on laboratory measurements. § Includes multiple adverse reaction terms. # Includes events with fata
Eintrag öffnenBrukinsa · 4.8 · 8 The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib in combination with obinutuzumab w
Eintrag öffnenBrukinsa · 4.8 · 9 Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · CTCAE) version 4.03. † Based on laboratory measurements. ± Percentages are based on number of patients with bo
Eintrag öffnenBrukinsa · 4.8 · CTCAE) version 4.03. † Based on laboratory measurements. ± Percentages are based on number of patients with bo
Eintrag öffnen